SSY Group (2005) investor relations material

Executive summary

• Revenue for 2025 was HK$4,165 million, down 27.8% year-over-year, with net profit dropping 55.6% to HK$471 million due to lower sales volumes, intensified competition, and policy headwinds.

• Gross margin declined to 41.6% from 50.4% year-over-year; EPS fell 55.2%.

• Major sales declines in large-volume parenteral solutions and ampoule injections, but export and select product lines showed growth.

• R&D pipeline robust with 202 products in development, 166 products passed consistency evaluation, and several new product approvals and clinical trials initiated.

• The Group maintained stable market share in key segments despite significant market and policy headwinds.

Financial highlights

• EBITDA decreased 43.3% year-over-year to HK$1,027 million; EBITDA margin fell to 24.7%.

• Dividend payout ratio was 49.7%, with total dividends of HK$234 million, down 54.9%; final dividend of HK$0.03 per share proposed, total annual dividend HK$0.08 per share, down 54.3%.

• Cash and equivalents rose to HK$1,691 million; net assets at HK$7,621 million; bank borrowings at HK$4,011 million.

• Gearing ratio at 24.1% (down from 24.8%); current ratio at 1.89 (down from 2.78).

• Operating profit margin: 15.1% (down from 23.3%); net profit margin: 11.3% (down from 18.4%).

Outlook and guidance

• Focus on expanding hospital and grassroots market coverage, leveraging national procurement wins, and expanding non-infusion products and overseas business.

• Plans to accelerate product launches, especially in dialysis and export markets, and optimize product mix.

• Continued investment in high-end generics, innovative drugs, intelligent manufacturing, and M&A opportunities.

• Management expects continued risks from weak domestic demand and policy changes.